According to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), real-world evidence (RWE) is the #1 trend in HEOR for 2020 and is playing an increasing role in health care decisions globally. Regulatory bodies such as the FDA and EMA have traditionally used RWE to monitor post-market safety and adverse events, but are now beginning to use RWE to make regulatory decisions. The healthcare community is using RWE increasingly to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice.
Our Real-World Evidence and Data Analytics (RWE/DA) team leverages data from sources such as medical charts, administrative claims data, electronic health records, registries, and government databases to answer questions about disease epidemiology, burden, treatment patterns, comparative effectiveness, and costs. The studies may also be used to populate and validate economic models, support strategic value messages, and integrate patient-reported outcomes (PROs) with other sources of data as appropriate.
Our ‘data agnostic’ approach ensures that we will aim to find the best dataset to meet your research question. This, along with our strategic insights on study design and innovative analyses, provide tailored, fit-for-purpose insights that demonstrate the real-world value of healthcare innovations and interventions.